Drug intelligence / Profile preview

ALA-5000

Development stage: Preclinical
Lead developer: Alar Pharmaceuticals
Modality: Small Molecules
Administration: Injectable

Overview

ALA-5000 is a sustained-release, long-acting injectable formulation developed for the treatment of schizophrenia. It utilizes Alar Pharmaceuticals' proprietary In-Relar sustained release drug delivery platform to provide extended therapeutic effects and improve medication adherence in patients with schizophrenia. As of the latest available information, ALA-5000 is in preclinical development[1][2].

Beyond the preview

Go deeper on ALA-5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALA-5000.

Explore the full profile